Briacell Therapeutics Corp
Research Briacell Therapeutics Corp (BCT) on Bullrun: market cap CAD 41.15M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerBCT
- ExchangeTO
- CountryCanada
- SectorHealthcare
- IndustryBiotechnology
- CurrencyCAD
- Market capCAD 41.15M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 7.16M
- Free cash flow-USD 7.15M
Valuation Snapshot
latest market cap is CAD 41.15M.
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-17 | CAD 41.15M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 CAD.
About Briacell Therapeutics Corp
BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Briacell Therapeutics Corp's market cap?
Briacell Therapeutics Corp's market capitalization is CAD 41.15M.
What does Briacell Therapeutics Corp do?
BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor.